1. Articles in category: Personalized Medicine

    1-24 of 41 1 2 »
    1. ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      Scientists from The Institute of Cancer Research, London, have been awarded £1.5 million by the charity Children with Cancer UK to advance precision medicine in the UK and improve cancer treatment for children and young adults.

      Read Full Article
      Mentions: Treatment
    2. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.

      Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.

      Genome Med. 2017 Feb 10;9(1):15

      Authors: Duffy DJ, Krstic A, Halasz M, Schwarzl T, Konietzny A, Iljin K, Higgins DG, Kolch W

      Abstract BACKGROUND: Retinoid therapy is widely employed in clinical oncology to differentiate malignant cells into their more benign counterparts.

      Read Full Article
      Mentions: MYCN
    3. New assay shows promise to advance personalized therapy for cancer patients

      New assay shows promise to advance personalized therapy for cancer patients

      ( Elsevier Health Sciences ) The National Cancer Institute's NCI-MATCH (Molecular Analysis for Therapy Choice) is a large, ongoing clinical trial that matches tumors to therapies based on the tumor's genetic characteristics. A report in The Journal of Molecular Diagnostics confirms that the assay tailored for this trial is highly sensitive for detecting genetic mutations from a variety of tumor tissue and, for the first time, has been reproduced with accuracy by multiple clinical laboratories, laying the groundwork for future clinical utility.

      Read Full Article
      Mentions: Diagnostics
    4. Does using biomarker to select patients for Phase 1 trials improve efficacy?

      Does using biomarker to select patients for Phase 1 trials improve efficacy?

      "These results argue strongly for the enrichment of phase 1 clinical trials with biomarker selection for targeted therapies. However, rigid exclusion based on biomarkers that have not been proven clinically could prove counterproductive in some cases," the authors conclude."

      Read Full Article
    5. Neuroblastoma: A Tough Nut to Crack.

      "These advances have resulted in a growing population of long-term survivors of neuroblastoma. Examination of the late effects and second malignant neoplasms (SMNs) in both older generations of survivors and more recently treated survivors will inform both design of future trials and surveillance guidelines for long-term follow-up. As a consequence of advances in understanding of the biology of neuroblastoma, successful clinical trials, and refined understanding of the late effects and SMNs of survivors, the promise of precision medicine is becoming a reality for patients with neuroblastoma."

      Read Full Article
      Mentions: Treatment MYCN
    6. Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.

      Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.

      Paediatr Drugs. 2016 May 3;

      Authors: Maagdenberg H, Vijverberg SJ, Bierings MB, Carleton BC, Arets HG, de Boer A, Maitland-van der Zee AH

      Abstract It is well known that drug responses differ among patients with regard to dose requirements, efficacy, and adverse drug reactions (ADRs). The differences in drug responses are partially explained by genetic variation.

      Read Full Article
    7. UCLA Study Yields the Key to Effective Personalized Medicine

      "Unlike other approaches to personalized medicine currently being tested, PPM doesn’t require complex, time-consuming analysis of a patient’s genetic information or of the disease’s cellular makeup. Instead, it produces a personalized drug regimen based on information about a person’s phenotype — biological traits that could include anything from blood pressure to the size of a tumor or the health of a specific organ."

      Read Full Article
    8. Patients with Advanced Cancer Want to Know Their Genomics Test Results

      "An overwhelming majority of people with incurable cancer want to hear findings from DNA sequencing of their own tumors and normal cells, and to learn how those results may affect their health and treatment options, Dana Farber Cancer Institute scientists report.  The discovery highlights the need to improve patient education about genomics and to boost the resources available for the oncologists who interpret and present these findings to the patients."

      Read Full Article
      Mentions: Treatment Genetics
    9. Pediatrics Data Platform Announced at White House Precision Medicine Initiative

      “The ‘big data’ genomics revolution presents us with unprecedented opportunities to improve treatments for pediatric brain tumors, which are the leading cause of disease-related death in children,” said Phillip Storm, M.D., division chief of Neurosurgery at CHOP and the Center’s co-director.  CHOP’s commitment to PMI is the product of collaborative efforts in pediatric cancer research that include a national network of more than 15 leading hospitals, numerous industry partners, foundations, patients and their families. The Cavatica system is central to these efforts, integrating a cloud-based, open infrastructure with big data analytics so that researchers can leverage a ...

      Read Full Article
      Mentions: Genetics
    10. Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE™ to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers

      “One of the biggest impediments to progress in the field of childhood cancer is the paucity of genomic data available from patients at the time of disease relapse. These data are critical to defining comprehensive strategies to precisely treat relapsed disease, and more importantly, to prevent disease recurrence in the first place,” stated John M. Maris, M.D., Giulio D'Angio Endowed Professor of Pediatric Oncology at Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania. “The data being made available from Foundation Medicine will serve as a tremendous resource for the cancer research ...

      Read Full Article
    11. Unique Next Generation Sequencing-Based Panel Designed for Pediatric Cancer Research

      Unique Next Generation Sequencing-Based Panel Designed for Pediatric Cancer Research

      "Children’s Hospital Los Angeles (CHLA) and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay would be CHLA’s first NGS panel designed to target biomarkers associated with childhood cancers.  The NGS panel under development is a unique targeted DNA and RNA sequencing-based research gene panel. Its results could lead to better understanding of the pathogenesis and future therapy of pediatric cancer patients. It will utilize Thermo Fisher’s Ion Torrent NGS platform and Ion AmpliSeq technology."

      Read Full Article
    12. Cancer MoonShot 2020 Announces the Formation of a National Pediatrics Consortium, a Major Milestone in the War on Cancer in Children

      PHOENIX--(BUSINESS WIRE)--In a press conference today, Cancer MoonShot 2020 announced another milestone in its quest to alter the course of cancer care with the formation of the Pediatrics Consortium focused on bringing the promise of combined immunotherapy as the next-generation standard of cancer care to children diagnosed with the disease. With leadership at Phoenix Children’s Hospital helping to initiate this consortium, all founding partners will seek to apply the most comprehensive cancer

      Read Full Article
      Mentions: Immunotherapy
    13. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.

      Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.

      JAMA Oncol. 2016 Jan 28;

      Authors: Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA

      Read Full Article
      Mentions: MYCN
    14. Genetic sequencing can help guide treatment in children with solid tumors

      Genetic sequencing can help guide treatment in children with solid tumors

      "The story of precision medicine in pediatric cancer is just starting," said Katherine Janeway, MD, lead iCat investigator and clinical director of the Solid Tumor Center at Dana-Farber/Boston Children's. "Ours and other studies show that if we do this kind of sequencing we might find treatment opportunities for children. And they provide openings for expanding our knowledge of the childhood cancer genome and helping both clinicians and basic scientists understand which treatments work for a given tumor, which don't and why, all of which could fuel additional drug development for both pediatric and rare adult tumors."

      Read Full Article
      Mentions: Treatment
    15. Genetic testing for childhood cancer patients can identify cause and treatment potential

      Genetic testing for childhood cancer patients can identify cause and treatment potential

      "More than 25 percent of patients in the study had a genetic mutation of potential clinical relevance detected in their tumor, including some that could guide selection of treatment in the event of tumor recurrence, reported Dr. Angshumoy Roy, assistant professor of pathology & immunology at Baylor and Texas Children's Hospital and one of the study contributors. Nearly 10 percent had germline mutations in adult and pediatric cancer susceptibility genes that explained the cause of their cancer, and additional patients had mutations in genes that were related to risk of diseases other than cancer.  "Our findings were much broader than ...

      Read Full Article
    16. Splicing Alterations That Cause Resistance to CD19 CAR T-cell Therapy Identified

      Bottom Line: Resistance to CD19 CAR T-cell therapy, a type of immunotherapy that yields long-lasting remissions in many patients with B-cell leukemia, can be caused by CD19 splicing alterations, leading to loss of certain parts of the CD19 protein that are recognized by the CAR T cells. Journal in Which the Study was Published: Cancer Discovery, a journal of the American Association for Cancer Research

      Read Full Article
    17. Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.

      Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.

      Clin Cancer Res. 2015 Oct 26;

      Authors: Mosse YP

      Abstract In this era of more rational therapies, substantial efforts are being made to identify optimal targets. The discovery of translocations involving the Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine.

      Read Full Article
    18. Pediatric targeted therapy: Clinical feasibility of personalized diagnostics in children with relapsed and progressive tumors.

      "In 93% of the cases potentially actionable targets were identified. The expressed or activated pathways were HDACs (83.0% of cases positive), EGFR (87.2%), PDGFR (75.9%), p53 (50.0%), MAPK/ERK (43.3%), and PI3K/mTOR (36.1%). Follow-up revealed partial or full implementation of PTT results in treatment decision making in 41% of the cases. Prolonged disease stabilization responses in single cases were noticed, however response rates did not differ from cases treated with other modalities. Further studies evaluating the feasibility and clinical benefit of personalized diagnostic approaches using paraffin material are warranted."

      Read Full Article
      Mentions: Diagnostics
    19. Precision Medicine Progress for Pediatric Cancer.

      Precision Medicine Progress for Pediatric Cancer.

      Cancer Discov. 2015 Sep 28;

      Authors:

      Abstract In a recent study, whole-exome and transcriptome sequencing identified potentially actionable findings that led to effective treatments for some children with advanced and rare cancers. The findings demonstrate that genomic sequencing data can be effectively integrated into the clinical management of pediatric patients.

      PMID: 26416572 [PubMed - as supplied by publisher]

      Read Full Article
    20. Clinical Validity of Molecular Profiling from Caris Life Sciences Confirmed by Study Demonstrating Increased Median Overall Survival and Clinical Impact on Treatment Decisions

      IRVING, Texas, Sept. 28, 2015 /PRNewswire/ -- Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announces the presentation of data from a six-year prospective, observational study in which Caris Molecular...

      Read Full Article
    21. Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)

      A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in subjects with newly diagnosed high risk neuroblastoma.

      ConditionInterventionPhase
      Neuroblastoma Drug: bortezomib
      Drug: crizotinib
      Drug: dasatinib
      Drug: lapatinib
      Drug: sorafenib
      Drug: vorinostat
      Drug: DFMO
      Phase 1
      Read Full Article
    22. CHOP Is a Founding Member of New NIH-Funded Research Consortium to Test New Cancer Treatments for Children

      “The primary rationale for this consortium is the fact that there are very few new drugs for pediatric cancer, and many of those drugs that have been introduced have been dependent on the results of clinical trials in adults,” said pediatric oncologist John M. Maris, M.D., who leads CHOP’s research program within the PPTC. Maris will collaborate on this project with CHOP co-investigators Dr. Edward Attiyeh, Dr. Lori Hart and Mr. Matthew Tang."

      Read Full Article
    1-24 of 41 1 2 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles